nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—CYP3A7—Docetaxel—head and neck cancer	0.0839	0.223	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0839	0.223	CbGbCtD
Sirolimus—CYP3A5—Docetaxel—head and neck cancer	0.0629	0.168	CbGbCtD
Sirolimus—ABCB1—Vinblastine—head and neck cancer	0.0497	0.132	CbGbCtD
Sirolimus—ABCB1—Docetaxel—head and neck cancer	0.041	0.109	CbGbCtD
Sirolimus—CYP3A4—Vinblastine—head and neck cancer	0.0298	0.0793	CbGbCtD
Sirolimus—CYP3A4—Docetaxel—head and neck cancer	0.0245	0.0653	CbGbCtD
Sirolimus—EIF4E—connective tissue—head and neck cancer	0.00373	0.113	CbGeAlD
Sirolimus—EIF4E—lymphoid tissue—head and neck cancer	0.00272	0.0827	CbGeAlD
Sirolimus—EIF4E—head—head and neck cancer	0.0022	0.0667	CbGeAlD
Sirolimus—MTOR—neck—head and neck cancer	0.00201	0.0611	CbGeAlD
Sirolimus—Polyp—Docetaxel—head and neck cancer	0.00192	0.00668	CcSEcCtD
Sirolimus—FGF2—trachea—head and neck cancer	0.00191	0.0579	CbGeAlD
Sirolimus—Oral candidiasis—Docetaxel—head and neck cancer	0.00183	0.0064	CcSEcCtD
Sirolimus—Hepatic failure—Hydroxyurea—head and neck cancer	0.00181	0.00632	CcSEcCtD
Sirolimus—FKBP1A—neck—head and neck cancer	0.00181	0.0549	CbGeAlD
Sirolimus—Nail disorder—Docetaxel—head and neck cancer	0.0018	0.00627	CcSEcCtD
Sirolimus—Cellulitis—Fluorouracil—head and neck cancer	0.00178	0.00619	CcSEcCtD
Sirolimus—Herpes simplex—Fluorouracil—head and neck cancer	0.00175	0.00611	CcSEcCtD
Sirolimus—Cyst—Docetaxel—head and neck cancer	0.00174	0.00608	CcSEcCtD
Sirolimus—Leukocytosis—Fluorouracil—head and neck cancer	0.00172	0.00599	CcSEcCtD
Sirolimus—Ileus—Docetaxel—head and neck cancer	0.00165	0.00574	CcSEcCtD
Sirolimus—Interstitial lung disease—Docetaxel—head and neck cancer	0.00165	0.00574	CcSEcCtD
Sirolimus—Face oedema—Hydroxyurea—head and neck cancer	0.00157	0.00548	CcSEcCtD
Sirolimus—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00153	0.00532	CcSEcCtD
Sirolimus—Pleural effusion—Docetaxel—head and neck cancer	0.00152	0.00531	CcSEcCtD
Sirolimus—Hepatotoxicity—Docetaxel—head and neck cancer	0.00151	0.00526	CcSEcCtD
Sirolimus—FGF2—thyroid gland—head and neck cancer	0.00151	0.0458	CbGeAlD
Sirolimus—Otitis media—Docetaxel—head and neck cancer	0.0015	0.00522	CcSEcCtD
Sirolimus—Oesophagitis—Fluorouracil—head and neck cancer	0.00148	0.00515	CcSEcCtD
Sirolimus—Breast disorder—Hydroxyurea—head and neck cancer	0.00147	0.00513	CcSEcCtD
Sirolimus—Pancytopenia—Vinblastine—head and neck cancer	0.00147	0.00511	CcSEcCtD
Sirolimus—MTOR—connective tissue—head and neck cancer	0.00144	0.0438	CbGeAlD
Sirolimus—Sepsis—Fluorouracil—head and neck cancer	0.0014	0.00489	CcSEcCtD
Sirolimus—Pancreatitis—Hydroxyurea—head and neck cancer	0.00138	0.00481	CcSEcCtD
Sirolimus—MTOR—epithelium—head and neck cancer	0.00137	0.0416	CbGeAlD
Sirolimus—Thrombophlebitis—Fluorouracil—head and neck cancer	0.00135	0.00472	CcSEcCtD
Sirolimus—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00135	0.0047	CcSEcCtD
Sirolimus—Pancytopenia—Hydroxyurea—head and neck cancer	0.00134	0.00466	CcSEcCtD
Sirolimus—Amenorrhoea—Docetaxel—head and neck cancer	0.00133	0.00463	CcSEcCtD
Sirolimus—Neutropenia—Hydroxyurea—head and neck cancer	0.00132	0.00459	CcSEcCtD
Sirolimus—Dysuria—Hydroxyurea—head and neck cancer	0.00132	0.00459	CcSEcCtD
Sirolimus—FKBP1A—connective tissue—head and neck cancer	0.0013	0.0394	CbGeAlD
Sirolimus—Bone disorder—Docetaxel—head and neck cancer	0.00129	0.0045	CcSEcCtD
Sirolimus—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00128	0.00447	CcSEcCtD
Sirolimus—Weight increased—Hydroxyurea—head and neck cancer	0.00128	0.00447	CcSEcCtD
Sirolimus—Oliguria—Docetaxel—head and neck cancer	0.00126	0.00441	CcSEcCtD
Sirolimus—Infestation—Hydroxyurea—head and neck cancer	0.00126	0.00438	CcSEcCtD
Sirolimus—Infestation NOS—Hydroxyurea—head and neck cancer	0.00126	0.00438	CcSEcCtD
Sirolimus—Haemoglobin—Vinblastine—head and neck cancer	0.00124	0.00433	CcSEcCtD
Sirolimus—Haemorrhage—Vinblastine—head and neck cancer	0.00124	0.00431	CcSEcCtD
Sirolimus—FKBP1A—epithelium—head and neck cancer	0.00123	0.0374	CbGeAlD
Sirolimus—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00123	0.00429	CcSEcCtD
Sirolimus—Hypoaesthesia—Vinblastine—head and neck cancer	0.00123	0.00429	CcSEcCtD
Sirolimus—Pharyngitis—Vinblastine—head and neck cancer	0.00123	0.00428	CcSEcCtD
Sirolimus—Stomatitis—Hydroxyurea—head and neck cancer	0.00122	0.00427	CcSEcCtD
Sirolimus—Bone pain—Docetaxel—head and neck cancer	0.00122	0.00424	CcSEcCtD
Sirolimus—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00119	0.00414	CcSEcCtD
Sirolimus—Osteoarthritis—Fluorouracil—head and neck cancer	0.00117	0.00409	CcSEcCtD
Sirolimus—Pulmonary embolism—Docetaxel—head and neck cancer	0.00117	0.00406	CcSEcCtD
Sirolimus—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00117	0.00406	CcSEcCtD
Sirolimus—Hepatocellular injury—Docetaxel—head and neck cancer	0.00117	0.00406	CcSEcCtD
Sirolimus—Haemoglobin—Hydroxyurea—head and neck cancer	0.00113	0.00395	CcSEcCtD
Sirolimus—Haemorrhage—Hydroxyurea—head and neck cancer	0.00113	0.00393	CcSEcCtD
Sirolimus—Hallucination—Hydroxyurea—head and neck cancer	0.00112	0.00391	CcSEcCtD
Sirolimus—Candida infection—Docetaxel—head and neck cancer	0.00111	0.00388	CcSEcCtD
Sirolimus—Fluid retention—Docetaxel—head and neck cancer	0.00111	0.00386	CcSEcCtD
Sirolimus—Neuropathy—Docetaxel—head and neck cancer	0.00109	0.00382	CcSEcCtD
Sirolimus—FKBP1A—trachea—head and neck cancer	0.00109	0.0331	CbGeAlD
Sirolimus—Oesophagitis—Docetaxel—head and neck cancer	0.00107	0.00371	CcSEcCtD
Sirolimus—MTOR—lymphoid tissue—head and neck cancer	0.00105	0.032	CbGeAlD
Sirolimus—Neoplasm—Docetaxel—head and neck cancer	0.00105	0.00367	CcSEcCtD
Sirolimus—Pulmonary oedema—Docetaxel—head and neck cancer	0.00104	0.00362	CcSEcCtD
Sirolimus—Angiopathy—Hydroxyurea—head and neck cancer	0.00102	0.00356	CcSEcCtD
Sirolimus—Dysphagia—Fluorouracil—head and neck cancer	0.00101	0.00353	CcSEcCtD
Sirolimus—Sepsis—Docetaxel—head and neck cancer	0.00101	0.00353	CcSEcCtD
Sirolimus—Chills—Hydroxyurea—head and neck cancer	0.00101	0.00352	CcSEcCtD
Sirolimus—Ill-defined disorder—Vinblastine—head and neck cancer	0.000998	0.00348	CcSEcCtD
Sirolimus—Anaemia—Vinblastine—head and neck cancer	0.000994	0.00347	CcSEcCtD
Sirolimus—Thrombophlebitis—Docetaxel—head and neck cancer	0.000977	0.00341	CcSEcCtD
Sirolimus—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000973	0.00339	CcSEcCtD
Sirolimus—Malaise—Vinblastine—head and neck cancer	0.00097	0.00338	CcSEcCtD
Sirolimus—Leukopenia—Vinblastine—head and neck cancer	0.000963	0.00336	CcSEcCtD
Sirolimus—Pancytopenia—Fluorouracil—head and neck cancer	0.000962	0.00335	CcSEcCtD
Sirolimus—MTOR—thyroid gland—head and neck cancer	0.000958	0.0291	CbGeAlD
Sirolimus—FKBP1A—lymphoid tissue—head and neck cancer	0.000948	0.0288	CbGeAlD
Sirolimus—Deafness—Docetaxel—head and neck cancer	0.000946	0.0033	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000942	0.00328	CcSEcCtD
Sirolimus—Hepatic failure—Docetaxel—head and neck cancer	0.000942	0.00328	CcSEcCtD
Sirolimus—FGF2—lymph node—head and neck cancer	0.000937	0.0285	CbGeAlD
Sirolimus—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000933	0.00325	CcSEcCtD
Sirolimus—Hypertension—Vinblastine—head and neck cancer	0.000929	0.00324	CcSEcCtD
Sirolimus—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00091	0.00317	CcSEcCtD
Sirolimus—Pneumonia—Fluorouracil—head and neck cancer	0.000909	0.00317	CcSEcCtD
Sirolimus—Anaemia—Hydroxyurea—head and neck cancer	0.000907	0.00316	CcSEcCtD
Sirolimus—Discomfort—Vinblastine—head and neck cancer	0.000905	0.00315	CcSEcCtD
Sirolimus—Infestation—Fluorouracil—head and neck cancer	0.000903	0.00315	CcSEcCtD
Sirolimus—Infestation NOS—Fluorouracil—head and neck cancer	0.000903	0.00315	CcSEcCtD
Sirolimus—Atrial fibrillation—Docetaxel—head and neck cancer	0.000893	0.00311	CcSEcCtD
Sirolimus—Renal impairment—Docetaxel—head and neck cancer	0.000889	0.0031	CcSEcCtD
Sirolimus—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000886	0.00309	CcSEcCtD
Sirolimus—Malaise—Hydroxyurea—head and neck cancer	0.000885	0.00308	CcSEcCtD
Sirolimus—Stomatitis—Fluorouracil—head and neck cancer	0.000881	0.00307	CcSEcCtD
Sirolimus—Conjunctivitis—Fluorouracil—head and neck cancer	0.000878	0.00306	CcSEcCtD
Sirolimus—Urinary tract infection—Fluorouracil—head and neck cancer	0.000878	0.00306	CcSEcCtD
Sirolimus—Leukopenia—Hydroxyurea—head and neck cancer	0.000878	0.00306	CcSEcCtD
Sirolimus—FKBP1A—thyroid gland—head and neck cancer	0.000861	0.0262	CbGeAlD
Sirolimus—Thrombocytopenia—Vinblastine—head and neck cancer	0.000859	0.003	CcSEcCtD
Sirolimus—Epistaxis—Fluorouracil—head and neck cancer	0.000852	0.00297	CcSEcCtD
Sirolimus—Hyponatraemia—Docetaxel—head and neck cancer	0.00085	0.00296	CcSEcCtD
Sirolimus—MTOR—head—head and neck cancer	0.000849	0.0258	CbGeAlD
Sirolimus—Sinusitis—Fluorouracil—head and neck cancer	0.000848	0.00296	CcSEcCtD
Sirolimus—Anorexia—Vinblastine—head and neck cancer	0.000837	0.00292	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000829	0.00289	CcSEcCtD
Sirolimus—Discomfort—Hydroxyurea—head and neck cancer	0.000825	0.00288	CcSEcCtD
Sirolimus—Haemoglobin—Fluorouracil—head and neck cancer	0.000815	0.00284	CcSEcCtD
Sirolimus—Rhinitis—Fluorouracil—head and neck cancer	0.000813	0.00283	CcSEcCtD
Sirolimus—Haemorrhage—Fluorouracil—head and neck cancer	0.000811	0.00283	CcSEcCtD
Sirolimus—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000807	0.00281	CcSEcCtD
Sirolimus—Pharyngitis—Fluorouracil—head and neck cancer	0.000805	0.00281	CcSEcCtD
Sirolimus—Oedema—Hydroxyurea—head and neck cancer	0.0008	0.00279	CcSEcCtD
Sirolimus—Infection—Hydroxyurea—head and neck cancer	0.000795	0.00277	CcSEcCtD
Sirolimus—Paraesthesia—Vinblastine—head and neck cancer	0.000788	0.00275	CcSEcCtD
Sirolimus—Dehydration—Docetaxel—head and neck cancer	0.000787	0.00274	CcSEcCtD
Sirolimus—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000785	0.00274	CcSEcCtD
Sirolimus—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000784	0.00273	CcSEcCtD
Sirolimus—Liver function test abnormal—Docetaxel—head and neck cancer	0.000781	0.00272	CcSEcCtD
Sirolimus—Skin disorder—Hydroxyurea—head and neck cancer	0.000778	0.00271	CcSEcCtD
Sirolimus—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000773	0.00269	CcSEcCtD
Sirolimus—Breast disorder—Docetaxel—head and neck cancer	0.000765	0.00267	CcSEcCtD
Sirolimus—FKBP1A—head—head and neck cancer	0.000764	0.0232	CbGeAlD
Sirolimus—Anorexia—Hydroxyurea—head and neck cancer	0.000763	0.00266	CcSEcCtD
Sirolimus—Decreased appetite—Vinblastine—head and neck cancer	0.000763	0.00266	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000762	0.00266	CcSEcCtD
Sirolimus—Pain—Vinblastine—head and neck cancer	0.000751	0.00262	CcSEcCtD
Sirolimus—Constipation—Vinblastine—head and neck cancer	0.000751	0.00262	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000746	0.0026	CcSEcCtD
Sirolimus—SLC47A1—thyroid gland—head and neck cancer	0.00074	0.0225	CbGeAlD
Sirolimus—Dysphagia—Docetaxel—head and neck cancer	0.000731	0.00255	CcSEcCtD
Sirolimus—Feeling abnormal—Vinblastine—head and neck cancer	0.000723	0.00252	CcSEcCtD
Sirolimus—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000718	0.0025	CcSEcCtD
Sirolimus—Dyspnoea—Hydroxyurea—head and neck cancer	0.000714	0.00249	CcSEcCtD
Sirolimus—Somnolence—Hydroxyurea—head and neck cancer	0.000712	0.00248	CcSEcCtD
Sirolimus—Dyspepsia—Hydroxyurea—head and neck cancer	0.000705	0.00246	CcSEcCtD
Sirolimus—Decreased appetite—Hydroxyurea—head and neck cancer	0.000696	0.00243	CcSEcCtD
Sirolimus—Pancytopenia—Docetaxel—head and neck cancer	0.000695	0.00242	CcSEcCtD
Sirolimus—Abdominal pain—Vinblastine—head and neck cancer	0.000694	0.00242	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000691	0.00241	CcSEcCtD
Sirolimus—Constipation—Hydroxyurea—head and neck cancer	0.000685	0.00239	CcSEcCtD
Sirolimus—Pain—Hydroxyurea—head and neck cancer	0.000685	0.00239	CcSEcCtD
Sirolimus—Neutropenia—Docetaxel—head and neck cancer	0.000684	0.00238	CcSEcCtD
Sirolimus—Weight increased—Docetaxel—head and neck cancer	0.000666	0.00232	CcSEcCtD
Sirolimus—Weight decreased—Docetaxel—head and neck cancer	0.000662	0.00231	CcSEcCtD
Sirolimus—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00066	0.0023	CcSEcCtD
Sirolimus—SLC47A1—head—head and neck cancer	0.000657	0.0199	CbGeAlD
Sirolimus—Pneumonia—Docetaxel—head and neck cancer	0.000656	0.00229	CcSEcCtD
Sirolimus—Anaemia—Fluorouracil—head and neck cancer	0.000653	0.00228	CcSEcCtD
Sirolimus—Infestation NOS—Docetaxel—head and neck cancer	0.000652	0.00227	CcSEcCtD
Sirolimus—Infestation—Docetaxel—head and neck cancer	0.000652	0.00227	CcSEcCtD
Sirolimus—Hypersensitivity—Vinblastine—head and neck cancer	0.000647	0.00225	CcSEcCtD
Sirolimus—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000639	0.00223	CcSEcCtD
Sirolimus—Stomatitis—Docetaxel—head and neck cancer	0.000636	0.00222	CcSEcCtD
Sirolimus—Conjunctivitis—Docetaxel—head and neck cancer	0.000634	0.00221	CcSEcCtD
Sirolimus—Body temperature increased—Hydroxyurea—head and neck cancer	0.000633	0.00221	CcSEcCtD
Sirolimus—Leukopenia—Fluorouracil—head and neck cancer	0.000632	0.0022	CcSEcCtD
Sirolimus—Asthenia—Vinblastine—head and neck cancer	0.00063	0.0022	CcSEcCtD
Sirolimus—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000617	0.00215	CcSEcCtD
Sirolimus—Epistaxis—Docetaxel—head and neck cancer	0.000615	0.00214	CcSEcCtD
Sirolimus—Chest pain—Fluorouracil—head and neck cancer	0.000601	0.0021	CcSEcCtD
Sirolimus—Myalgia—Fluorouracil—head and neck cancer	0.000601	0.0021	CcSEcCtD
Sirolimus—Diarrhoea—Vinblastine—head and neck cancer	0.000601	0.00209	CcSEcCtD
Sirolimus—MTOR—lymph node—head and neck cancer	0.000595	0.0181	CbGeAlD
Sirolimus—Discomfort—Fluorouracil—head and neck cancer	0.000594	0.00207	CcSEcCtD
Sirolimus—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00059	0.00206	CcSEcCtD
Sirolimus—Haemoglobin—Docetaxel—head and neck cancer	0.000588	0.00205	CcSEcCtD
Sirolimus—Rhinitis—Docetaxel—head and neck cancer	0.000587	0.00205	CcSEcCtD
Sirolimus—Haemorrhage—Docetaxel—head and neck cancer	0.000585	0.00204	CcSEcCtD
Sirolimus—Hypoaesthesia—Docetaxel—head and neck cancer	0.000582	0.00203	CcSEcCtD
Sirolimus—Confusional state—Fluorouracil—head and neck cancer	0.000581	0.00203	CcSEcCtD
Sirolimus—Pharyngitis—Docetaxel—head and neck cancer	0.000581	0.00203	CcSEcCtD
Sirolimus—Dizziness—Vinblastine—head and neck cancer	0.00058	0.00202	CcSEcCtD
Sirolimus—Urinary tract disorder—Docetaxel—head and neck cancer	0.000578	0.00202	CcSEcCtD
Sirolimus—Oedema peripheral—Docetaxel—head and neck cancer	0.000577	0.00201	CcSEcCtD
Sirolimus—Oedema—Fluorouracil—head and neck cancer	0.000576	0.00201	CcSEcCtD
Sirolimus—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000576	0.00201	CcSEcCtD
Sirolimus—Connective tissue disorder—Docetaxel—head and neck cancer	0.000575	0.00201	CcSEcCtD
Sirolimus—Asthenia—Hydroxyurea—head and neck cancer	0.000574	0.002	CcSEcCtD
Sirolimus—Urethral disorder—Docetaxel—head and neck cancer	0.000574	0.002	CcSEcCtD
Sirolimus—Infection—Fluorouracil—head and neck cancer	0.000572	0.002	CcSEcCtD
Sirolimus—Nervous system disorder—Fluorouracil—head and neck cancer	0.000565	0.00197	CcSEcCtD
Sirolimus—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000564	0.00197	CcSEcCtD
Sirolimus—Visual impairment—Docetaxel—head and neck cancer	0.000564	0.00197	CcSEcCtD
Sirolimus—Tachycardia—Fluorouracil—head and neck cancer	0.000562	0.00196	CcSEcCtD
Sirolimus—Vomiting—Vinblastine—head and neck cancer	0.000558	0.00195	CcSEcCtD
Sirolimus—Headache—Vinblastine—head and neck cancer	0.00055	0.00192	CcSEcCtD
Sirolimus—Anorexia—Fluorouracil—head and neck cancer	0.000549	0.00191	CcSEcCtD
Sirolimus—Diarrhoea—Hydroxyurea—head and neck cancer	0.000548	0.00191	CcSEcCtD
Sirolimus—Cardiac disorder—Docetaxel—head and neck cancer	0.000543	0.00189	CcSEcCtD
Sirolimus—Hypotension—Fluorouracil—head and neck cancer	0.000538	0.00188	CcSEcCtD
Sirolimus—FKBP1A—lymph node—head and neck cancer	0.000535	0.0162	CbGeAlD
Sirolimus—Angiopathy—Docetaxel—head and neck cancer	0.000531	0.00185	CcSEcCtD
Sirolimus—Dizziness—Hydroxyurea—head and neck cancer	0.000529	0.00185	CcSEcCtD
Sirolimus—Immune system disorder—Docetaxel—head and neck cancer	0.000529	0.00184	CcSEcCtD
Sirolimus—Mediastinal disorder—Docetaxel—head and neck cancer	0.000528	0.00184	CcSEcCtD
Sirolimus—Chills—Docetaxel—head and neck cancer	0.000525	0.00183	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000525	0.00183	CcSEcCtD
Sirolimus—Nausea—Vinblastine—head and neck cancer	0.000521	0.00182	CcSEcCtD
Sirolimus—Insomnia—Fluorouracil—head and neck cancer	0.000521	0.00182	CcSEcCtD
Sirolimus—Paraesthesia—Fluorouracil—head and neck cancer	0.000517	0.0018	CcSEcCtD
Sirolimus—Dyspnoea—Fluorouracil—head and neck cancer	0.000514	0.00179	CcSEcCtD
Sirolimus—Somnolence—Fluorouracil—head and neck cancer	0.000512	0.00179	CcSEcCtD
Sirolimus—Malnutrition—Docetaxel—head and neck cancer	0.00051	0.00178	CcSEcCtD
Sirolimus—Vomiting—Hydroxyurea—head and neck cancer	0.000509	0.00177	CcSEcCtD
Sirolimus—Dyspepsia—Fluorouracil—head and neck cancer	0.000507	0.00177	CcSEcCtD
Sirolimus—Rash—Hydroxyurea—head and neck cancer	0.000505	0.00176	CcSEcCtD
Sirolimus—Dermatitis—Hydroxyurea—head and neck cancer	0.000504	0.00176	CcSEcCtD
Sirolimus—Headache—Hydroxyurea—head and neck cancer	0.000501	0.00175	CcSEcCtD
Sirolimus—Decreased appetite—Fluorouracil—head and neck cancer	0.000501	0.00175	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000497	0.00173	CcSEcCtD
Sirolimus—Back pain—Docetaxel—head and neck cancer	0.000493	0.00172	CcSEcCtD
Sirolimus—Pain—Fluorouracil—head and neck cancer	0.000493	0.00172	CcSEcCtD
Sirolimus—Muscle spasms—Docetaxel—head and neck cancer	0.00049	0.00171	CcSEcCtD
Sirolimus—Nausea—Hydroxyurea—head and neck cancer	0.000475	0.00166	CcSEcCtD
Sirolimus—Feeling abnormal—Fluorouracil—head and neck cancer	0.000475	0.00166	CcSEcCtD
Sirolimus—Anaemia—Docetaxel—head and neck cancer	0.000471	0.00164	CcSEcCtD
Sirolimus—SLC47A1—lymph node—head and neck cancer	0.00046	0.014	CbGeAlD
Sirolimus—Syncope—Docetaxel—head and neck cancer	0.000457	0.00159	CcSEcCtD
Sirolimus—Leukopenia—Docetaxel—head and neck cancer	0.000456	0.00159	CcSEcCtD
Sirolimus—Body temperature increased—Fluorouracil—head and neck cancer	0.000455	0.00159	CcSEcCtD
Sirolimus—Palpitations—Docetaxel—head and neck cancer	0.00045	0.00157	CcSEcCtD
Sirolimus—Loss of consciousness—Docetaxel—head and neck cancer	0.000448	0.00156	CcSEcCtD
Sirolimus—Cough—Docetaxel—head and neck cancer	0.000445	0.00155	CcSEcCtD
Sirolimus—Hypertension—Docetaxel—head and neck cancer	0.00044	0.00153	CcSEcCtD
Sirolimus—Arthralgia—Docetaxel—head and neck cancer	0.000434	0.00151	CcSEcCtD
Sirolimus—Myalgia—Docetaxel—head and neck cancer	0.000434	0.00151	CcSEcCtD
Sirolimus—Chest pain—Docetaxel—head and neck cancer	0.000434	0.00151	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000431	0.0015	CcSEcCtD
Sirolimus—Hypersensitivity—Fluorouracil—head and neck cancer	0.000425	0.00148	CcSEcCtD
Sirolimus—Confusional state—Docetaxel—head and neck cancer	0.000419	0.00146	CcSEcCtD
Sirolimus—Anaphylactic shock—Docetaxel—head and neck cancer	0.000416	0.00145	CcSEcCtD
Sirolimus—Oedema—Docetaxel—head and neck cancer	0.000416	0.00145	CcSEcCtD
Sirolimus—Infection—Docetaxel—head and neck cancer	0.000413	0.00144	CcSEcCtD
Sirolimus—Shock—Docetaxel—head and neck cancer	0.000409	0.00143	CcSEcCtD
Sirolimus—Nervous system disorder—Docetaxel—head and neck cancer	0.000408	0.00142	CcSEcCtD
Sirolimus—Pruritus—Fluorouracil—head and neck cancer	0.000408	0.00142	CcSEcCtD
Sirolimus—Thrombocytopenia—Docetaxel—head and neck cancer	0.000407	0.00142	CcSEcCtD
Sirolimus—Tachycardia—Docetaxel—head and neck cancer	0.000406	0.00142	CcSEcCtD
Sirolimus—Skin disorder—Docetaxel—head and neck cancer	0.000404	0.00141	CcSEcCtD
Sirolimus—Anorexia—Docetaxel—head and neck cancer	0.000396	0.00138	CcSEcCtD
Sirolimus—Diarrhoea—Fluorouracil—head and neck cancer	0.000394	0.00137	CcSEcCtD
Sirolimus—Hypotension—Docetaxel—head and neck cancer	0.000389	0.00135	CcSEcCtD
Sirolimus—Dizziness—Fluorouracil—head and neck cancer	0.000381	0.00133	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000379	0.00132	CcSEcCtD
Sirolimus—Insomnia—Docetaxel—head and neck cancer	0.000376	0.00131	CcSEcCtD
Sirolimus—Paraesthesia—Docetaxel—head and neck cancer	0.000373	0.0013	CcSEcCtD
Sirolimus—Dyspnoea—Docetaxel—head and neck cancer	0.000371	0.00129	CcSEcCtD
Sirolimus—Somnolence—Docetaxel—head and neck cancer	0.00037	0.00129	CcSEcCtD
Sirolimus—Vomiting—Fluorouracil—head and neck cancer	0.000366	0.00128	CcSEcCtD
Sirolimus—Dyspepsia—Docetaxel—head and neck cancer	0.000366	0.00128	CcSEcCtD
Sirolimus—Rash—Fluorouracil—head and neck cancer	0.000363	0.00127	CcSEcCtD
Sirolimus—Dermatitis—Fluorouracil—head and neck cancer	0.000363	0.00127	CcSEcCtD
Sirolimus—Decreased appetite—Docetaxel—head and neck cancer	0.000362	0.00126	CcSEcCtD
Sirolimus—Headache—Fluorouracil—head and neck cancer	0.000361	0.00126	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000359	0.00125	CcSEcCtD
Sirolimus—Constipation—Docetaxel—head and neck cancer	0.000356	0.00124	CcSEcCtD
Sirolimus—Pain—Docetaxel—head and neck cancer	0.000356	0.00124	CcSEcCtD
Sirolimus—Feeling abnormal—Docetaxel—head and neck cancer	0.000343	0.00119	CcSEcCtD
Sirolimus—Nausea—Fluorouracil—head and neck cancer	0.000342	0.00119	CcSEcCtD
Sirolimus—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00034	0.00119	CcSEcCtD
Sirolimus—Abdominal pain—Docetaxel—head and neck cancer	0.000329	0.00115	CcSEcCtD
Sirolimus—Body temperature increased—Docetaxel—head and neck cancer	0.000329	0.00115	CcSEcCtD
Sirolimus—Hypersensitivity—Docetaxel—head and neck cancer	0.000306	0.00107	CcSEcCtD
Sirolimus—Asthenia—Docetaxel—head and neck cancer	0.000298	0.00104	CcSEcCtD
Sirolimus—Pruritus—Docetaxel—head and neck cancer	0.000294	0.00103	CcSEcCtD
Sirolimus—ABCB1—epithelium—head and neck cancer	0.000285	0.00865	CbGeAlD
Sirolimus—Diarrhoea—Docetaxel—head and neck cancer	0.000285	0.000992	CcSEcCtD
Sirolimus—Dizziness—Docetaxel—head and neck cancer	0.000275	0.000959	CcSEcCtD
Sirolimus—Vomiting—Docetaxel—head and neck cancer	0.000264	0.000922	CcSEcCtD
Sirolimus—Rash—Docetaxel—head and neck cancer	0.000262	0.000914	CcSEcCtD
Sirolimus—Dermatitis—Docetaxel—head and neck cancer	0.000262	0.000913	CcSEcCtD
Sirolimus—Headache—Docetaxel—head and neck cancer	0.000261	0.000908	CcSEcCtD
Sirolimus—ABCB1—trachea—head and neck cancer	0.000252	0.00765	CbGeAlD
Sirolimus—Nausea—Docetaxel—head and neck cancer	0.000247	0.000861	CcSEcCtD
Sirolimus—ABCB1—lymphoid tissue—head and neck cancer	0.000219	0.00666	CbGeAlD
Sirolimus—ABCB1—thyroid gland—head and neck cancer	0.000199	0.00605	CbGeAlD
Sirolimus—ABCB1—head—head and neck cancer	0.000177	0.00537	CbGeAlD
Sirolimus—ABCB1—lymph node—head and neck cancer	0.000124	0.00376	CbGeAlD
Sirolimus—FGF2—Signaling by NGF—HRAS—head and neck cancer	0.000111	0.000365	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—MAPK1—head and neck cancer	0.00011	0.00036	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GRP—head and neck cancer	0.000108	0.000355	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL2—head and neck cancer	0.000108	0.000355	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MAPK3—head and neck cancer	0.000108	0.000354	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	0.000107	0.000352	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	0.000107	0.000351	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—AKT1—head and neck cancer	0.000107	0.000351	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—AKT1—head and neck cancer	0.000107	0.000351	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NOTCH1—head and neck cancer	0.000106	0.000349	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—AKT1—head and neck cancer	0.000106	0.000348	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000106	0.000347	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NAT2—head and neck cancer	0.000106	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT6—head and neck cancer	0.000105	0.000345	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—head and neck cancer	0.000105	0.000345	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—AKT1—head and neck cancer	0.000105	0.000343	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MAPK1—head and neck cancer	0.000103	0.000337	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—head and neck cancer	0.000103	0.000337	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000102	0.000336	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PTEN—head and neck cancer	0.000102	0.000334	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NOTCH1—head and neck cancer	0.000102	0.000334	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CASP8—head and neck cancer	0.000101	0.000333	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	0.000101	0.000333	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000101	0.000332	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—DPYD—head and neck cancer	0.000101	0.000331	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—VEGFA—head and neck cancer	9.93e-05	0.000326	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—AKT1—head and neck cancer	9.89e-05	0.000325	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—STAT3—head and neck cancer	9.84e-05	0.000323	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—AKT1—head and neck cancer	9.81e-05	0.000322	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BCL2L1—head and neck cancer	9.73e-05	0.00032	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PTEN—head and neck cancer	9.71e-05	0.000319	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	9.71e-05	0.000319	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDH1—head and neck cancer	9.62e-05	0.000316	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	9.57e-05	0.000314	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—YAP1—head and neck cancer	9.57e-05	0.000314	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	9.47e-05	0.000311	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MAPK3—head and neck cancer	9.4e-05	0.000308	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PTEN—head and neck cancer	9.33e-05	0.000306	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—YAP1—head and neck cancer	9.3e-05	0.000305	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—DPYD—head and neck cancer	9.25e-05	0.000304	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—head and neck cancer	9.19e-05	0.000302	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—STAT3—head and neck cancer	9.1e-05	0.000299	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	9.07e-05	0.000298	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MAPK1—head and neck cancer	8.94e-05	0.000294	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—head and neck cancer	8.94e-05	0.000293	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—PIK3CA—head and neck cancer	8.91e-05	0.000293	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—YAP1—head and neck cancer	8.78e-05	0.000288	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—BCL2—head and neck cancer	8.7e-05	0.000286	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MAPK3—head and neck cancer	8.69e-05	0.000285	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MAPK3—head and neck cancer	8.65e-05	0.000284	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	8.62e-05	0.000283	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UROD—head and neck cancer	8.54e-05	0.00028	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MAPK3—head and neck cancer	8.3e-05	0.000272	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MAPK1—head and neck cancer	8.27e-05	0.000272	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—head and neck cancer	8.27e-05	0.000272	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—HRAS—head and neck cancer	8.25e-05	0.000271	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOTCH1—head and neck cancer	8.07e-05	0.000265	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CASP8—head and neck cancer	7.96e-05	0.000261	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—head and neck cancer	7.9e-05	0.000259	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MAPK1—head and neck cancer	7.9e-05	0.000259	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—head and neck cancer	7.89e-05	0.000259	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDH1—head and neck cancer	7.86e-05	0.000258	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	7.79e-05	0.000256	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NAT2—head and neck cancer	7.63e-05	0.00025	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—head and neck cancer	7.58e-05	0.000249	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	7.51e-05	0.000247	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOTCH1—head and neck cancer	7.45e-05	0.000245	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—AKT1—head and neck cancer	7.28e-05	0.000239	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BCL2L1—head and neck cancer	7.22e-05	0.000237	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PTEN—head and neck cancer	7.21e-05	0.000237	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.19e-05	0.000236	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PIK3CA—head and neck cancer	7.18e-05	0.000236	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HRAS—head and neck cancer	7.18e-05	0.000236	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—head and neck cancer	6.99e-05	0.00023	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PTEN—head and neck cancer	6.92e-05	0.000227	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTEN—head and neck cancer	6.89e-05	0.000226	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PIK3CA—head and neck cancer	6.85e-05	0.000225	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BCL2—head and neck cancer	6.83e-05	0.000224	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—head and neck cancer	6.82e-05	0.000224	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	6.79e-05	0.000223	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—DPYD—head and neck cancer	6.69e-05	0.00022	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HRAS—head and neck cancer	6.64e-05	0.000218	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PIK3CA—head and neck cancer	6.58e-05	0.000216	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTEN—head and neck cancer	6.58e-05	0.000216	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	6.42e-05	0.000211	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—YAP1—head and neck cancer	6.35e-05	0.000208	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—HRAS—head and neck cancer	6.34e-05	0.000208	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—AKT1—head and neck cancer	6.34e-05	0.000208	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.27e-05	0.000206	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—STAT3—head and neck cancer	6.16e-05	0.000202	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK3—head and neck cancer	6.16e-05	0.000202	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	6.11e-05	0.000201	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	6.11e-05	0.000201	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—head and neck cancer	6.09e-05	0.0002	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—head and neck cancer	6.01e-05	0.000197	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—head and neck cancer	5.99e-05	0.000197	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOTCH1—head and neck cancer	5.99e-05	0.000197	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—head and neck cancer	5.94e-05	0.000195	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CASP8—head and neck cancer	5.9e-05	0.000194	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MAPK3—head and neck cancer	5.89e-05	0.000193	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STAT3—head and neck cancer	5.88e-05	0.000193	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—head and neck cancer	5.86e-05	0.000193	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK1—head and neck cancer	5.86e-05	0.000192	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—head and neck cancer	5.86e-05	0.000192	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDH1—head and neck cancer	5.83e-05	0.000192	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—head and neck cancer	5.83e-05	0.000191	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NAT2—head and neck cancer	5.75e-05	0.000189	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TYMS—head and neck cancer	5.74e-05	0.000189	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTM1—head and neck cancer	5.68e-05	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PTEN—head and neck cancer	5.66e-05	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOTCH1—head and neck cancer	5.65e-05	0.000185	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—head and neck cancer	5.63e-05	0.000185	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK3—head and neck cancer	5.62e-05	0.000185	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MAPK1—head and neck cancer	5.6e-05	0.000184	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—head and neck cancer	5.6e-05	0.000184	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—head and neck cancer	5.6e-05	0.000184	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GPX1—head and neck cancer	5.44e-05	0.000178	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP1A1—head and neck cancer	5.38e-05	0.000177	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—head and neck cancer	5.37e-05	0.000176	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK1—head and neck cancer	5.35e-05	0.000176	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—head and neck cancer	5.35e-05	0.000176	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	5.3e-05	0.000174	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TYMS—head and neck cancer	5.27e-05	0.000173	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTEN—head and neck cancer	5.22e-05	0.000171	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTM1—head and neck cancer	5.21e-05	0.000171	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—head and neck cancer	5.13e-05	0.000168	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	5.13e-05	0.000168	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—head and neck cancer	5.08e-05	0.000167	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BCL2—head and neck cancer	5.07e-05	0.000166	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—head and neck cancer	5.06e-05	0.000166	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DPYD—head and neck cancer	5.05e-05	0.000166	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—head and neck cancer	5e-05	0.000164	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GPX1—head and neck cancer	4.99e-05	0.000164	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP1A1—head and neck cancer	4.94e-05	0.000162	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—head and neck cancer	4.88e-05	0.00016	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—head and neck cancer	4.86e-05	0.00016	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK3—head and neck cancer	4.83e-05	0.000159	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—head and neck cancer	4.83e-05	0.000158	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—YAP1—head and neck cancer	4.79e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—head and neck cancer	4.7e-05	0.000154	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—head and neck cancer	4.67e-05	0.000153	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—head and neck cancer	4.64e-05	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK1—head and neck cancer	4.6e-05	0.000151	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—head and neck cancer	4.6e-05	0.000151	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—head and neck cancer	4.52e-05	0.000148	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—head and neck cancer	4.5e-05	0.000148	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—head and neck cancer	4.49e-05	0.000147	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK3—head and neck cancer	4.46e-05	0.000147	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—head and neck cancer	4.46e-05	0.000146	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—head and neck cancer	4.44e-05	0.000146	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.42e-05	0.000145	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—head and neck cancer	4.36e-05	0.000143	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	4.33e-05	0.000142	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—head and neck cancer	4.32e-05	0.000142	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—head and neck cancer	4.29e-05	0.000141	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK1—head and neck cancer	4.25e-05	0.000139	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—head and neck cancer	4.25e-05	0.000139	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—head and neck cancer	4.2e-05	0.000138	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH1—head and neck cancer	4.19e-05	0.000138	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—head and neck cancer	4.15e-05	0.000136	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK3—head and neck cancer	4.12e-05	0.000135	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—head and neck cancer	3.99e-05	0.000131	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—head and neck cancer	3.99e-05	0.000131	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—head and neck cancer	3.97e-05	0.00013	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK1—head and neck cancer	3.92e-05	0.000129	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—head and neck cancer	3.92e-05	0.000129	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—head and neck cancer	3.89e-05	0.000128	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—head and neck cancer	3.88e-05	0.000127	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—head and neck cancer	3.81e-05	0.000125	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—head and neck cancer	3.79e-05	0.000124	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—head and neck cancer	3.79e-05	0.000124	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—head and neck cancer	3.77e-05	0.000124	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—head and neck cancer	3.75e-05	0.000123	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—head and neck cancer	3.69e-05	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—head and neck cancer	3.68e-05	0.000121	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—head and neck cancer	3.66e-05	0.00012	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPX1—head and neck cancer	3.61e-05	0.000118	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK3—head and neck cancer	3.59e-05	0.000118	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A1—head and neck cancer	3.57e-05	0.000117	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NAT2—head and neck cancer	3.55e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—head and neck cancer	3.47e-05	0.000114	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK1—head and neck cancer	3.41e-05	0.000112	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—head and neck cancer	3.41e-05	0.000112	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—head and neck cancer	3.41e-05	0.000112	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—head and neck cancer	3.4e-05	0.000112	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK3—head and neck cancer	3.31e-05	0.000109	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—head and neck cancer	3.3e-05	0.000108	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—head and neck cancer	3.29e-05	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—head and neck cancer	3.27e-05	0.000107	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—head and neck cancer	3.26e-05	0.000107	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—head and neck cancer	3.2e-05	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK1—head and neck cancer	3.15e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—head and neck cancer	3.15e-05	0.000103	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—head and neck cancer	3.15e-05	0.000103	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK3—head and neck cancer	3.12e-05	0.000103	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DPYD—head and neck cancer	3.11e-05	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—head and neck cancer	3.01e-05	9.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK1—head and neck cancer	2.97e-05	9.76e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—head and neck cancer	2.97e-05	9.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—head and neck cancer	2.96e-05	9.72e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—YAP1—head and neck cancer	2.95e-05	9.69e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—head and neck cancer	2.94e-05	9.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—head and neck cancer	2.88e-05	9.47e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—head and neck cancer	2.88e-05	9.44e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—head and neck cancer	2.84e-05	9.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—head and neck cancer	2.81e-05	9.23e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—head and neck cancer	2.79e-05	9.16e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—head and neck cancer	2.78e-05	9.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—head and neck cancer	2.74e-05	9e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—head and neck cancer	2.73e-05	8.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPX1—head and neck cancer	2.72e-05	8.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—head and neck cancer	2.71e-05	8.91e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.69e-05	8.85e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—head and neck cancer	2.58e-05	8.47e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—head and neck cancer	2.56e-05	8.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—head and neck cancer	2.53e-05	8.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—head and neck cancer	2.5e-05	8.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—head and neck cancer	2.45e-05	8.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—head and neck cancer	2.43e-05	7.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—head and neck cancer	2.42e-05	7.94e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—head and neck cancer	2.39e-05	7.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK3—head and neck cancer	2.32e-05	7.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—head and neck cancer	2.23e-05	7.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK1—head and neck cancer	2.21e-05	7.24e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—head and neck cancer	2.21e-05	7.24e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—head and neck cancer	2.12e-05	6.97e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—head and neck cancer	2.11e-05	6.92e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—head and neck cancer	1.97e-05	6.47e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—head and neck cancer	1.91e-05	6.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—head and neck cancer	1.85e-05	6.08e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—head and neck cancer	1.85e-05	6.08e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—head and neck cancer	1.81e-05	5.93e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—head and neck cancer	1.77e-05	5.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—head and neck cancer	1.77e-05	5.82e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.75e-05	5.75e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPX1—head and neck cancer	1.68e-05	5.51e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.66e-05	5.45e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—head and neck cancer	1.61e-05	5.28e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—head and neck cancer	1.6e-05	5.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—head and neck cancer	1.56e-05	5.14e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—head and neck cancer	1.48e-05	4.85e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—head and neck cancer	1.4e-05	4.59e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—head and neck cancer	1.31e-05	4.29e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—head and neck cancer	1.07e-05	3.5e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—head and neck cancer	9.87e-06	3.24e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—head and neck cancer	9.86e-06	3.24e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—head and neck cancer	8.61e-06	2.83e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—head and neck cancer	8.05e-06	2.64e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—head and neck cancer	6.07e-06	1.99e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—head and neck cancer	4.96e-06	1.63e-05	CbGpPWpGaD
